Literature DB >> 24722805

Renin-angiotensin system blockade: time for a reappraisal?

Luis M Ruilope1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24722805      PMCID： PMC5994824          DOI： 10.1093/eurheartj/ehu129

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  19 in total

1.  Long-term adherence to therapy: the clue to prevent hypertension consequences.

Authors:  Luis M Ruilope
Journal:  Eur Heart J       Date:  2013-08-29       Impact factor: 29.983

2.  Validation of a therapeutic scheme for the treatment of resistant hypertension.

Authors:  Julian Segura; Cesar Cerezo; Jose A Garcia-Donaire; Roland E Schmieder; Manuel Praga; Alejandro de la Sierra; Luis M Ruilope
Journal:  J Am Soc Hypertens       Date:  2011-10-01

3.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

Review 4.  Current challenges in the clinical management of hypertension.

Authors:  Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

5.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

6.  Aliskiren.

Authors:  Morris J Brown
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

Review 7.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

8.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

Review 9.  Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.

Authors:  T Ninomiya; V Perkovic; F Turnbull; B Neal; F Barzi; A Cass; C Baigent; J Chalmers; N Li; M Woodward; S MacMahon
Journal:  BMJ       Date:  2013-10-03

10.  Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2013-04-05       Impact factor: 15.534
View more
  1 in total

Review 1.  Global cardiovascular protection in chronic kidney disease.

Authors:  Gema Ruiz-Hurtado; Pantelis Sarafidis; María S Fernández-Alfonso; Bernard Waeber; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.